Israel-based Kamada Ltd announced this week that it has entered into an agreement with Iceland-based Alvotech to commercialize 6 biosimilar products in Israel once the products gain local regulatory approval.
Israel-based Kamada Ltd announced this week that it has entered into an agreement with Iceland-based Alvotech to commercialize 6 biosimilar products in Israel once the products gain local regulatory approval.
Among the products that will be sold by Kamada is PF708, a teriparatide biosimilar that was also recently approved in the United States—as a follow-on product—and that is licensed to Pfenex. Alvotech’s sister company, Alvogen, will be Pfenex’s US commercialization partner, per an October announcement from the drug makers.
In the Israeli market, an additional 5 undisclosed products are expected to be launched between 2023 and 2025.
The current market for the reference products of the 6 biosimilars covered by the agreement is estimated to be $125 million to $150 million per year in Israel, and based on anticipated market penetration and price competition after biosimilar introduction, Kamada estimates that it will be able to achieve sales of $20 million to $30 million per year.
“Our partnership with Alvotech will leverage our existing commercial infrastructure in Israel and enable Kamada to benefit from the long-term growth potential of the emerging class of biosimilar drugs,” said Amir London, chief executive officer (CEO) of Kamada, in a statement announcing the deal.
Mark Levick, CEO of Alvotech, added, “We are delighted to establish this important partnership with Kamada, who is an ideal commercial partner in Israel. Together, we will provide patients with better access to high-quality and cost-effective biosimilar medicines.”
This latest deal follows shortly after Alvotech formed several additional partnerships; in November, the drug maker announced that it has entered into an exclusive partnership with Germany-based Stada to commercialize 7 biosimilars—including autoimmune, oncology, ophthalmology, and inflammatory disease therapies—in Europe. In September, it announced a contract manufacturing partnership with Singapore’s Prestige Biopharma. Finally, in April, it announced a deal with Fuji Pharma to sell a biosimilar ustekinumab in Japan.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.